logo
Kraft Heinz pulling certain artificial dyes from its US products in 2027

Kraft Heinz pulling certain artificial dyes from its US products in 2027

Globe and Mail17-06-2025
Kraft Heinz will be pulling certain artificial dyes from its U.S. products starting in 2027 and will no longer roll out new products with the dyes.
The move comes nearly two months after U.S. health officials said that they would urge foodmakers to phase out petroleum-based artificial colors in the nation's food supply.
Kraft Heinz said Tuesday that almost 90% of its U.S. products already don't contain food, drug & cosmetic colors, but that the products that do still use the dyes will have them removed by the end of 2027. FD&C colors are synthetic additives that are approved by the U.S. Food and Drug Administration for use in food, drugs and cosmetics.
The company said that it will instead use natural colors for the products.
'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio," Pedro Navio, North America President at Kraft Heinz, said in a statement.
Kraft Heinz stripped artificial colors, flavors and preservatives from its macaroni and cheese in 2016 and said it has never used artificial dyes in its ketchup.
The company plans to work with licensees of its brands to encourage them to remove the dyes.
In April Food and Drug Administration Commissioner Marty Makary said at a news conference that the agency would take steps to eliminate the synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry.
Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.'
The FDA currently allows 36 food color additives, including eight synthetic dyes. In January, the agency announced that the dye known as Red 3 — used in candies, cakes and some medications — would be banned in food by 2027 because it caused cancer in laboratory rats.
Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods.
Many U.S. food companies are already reformulating their foods, according to Sensient Colors, one of the world's largest producers of food dyes and flavorings. In place of synthetic dyes, foodmakers can use natural hues made from beets, algae and crushed insects and pigments from purple sweet potatoes, radishes and red cabbage.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Manhattan Laser Spa Continues to Set the Standard for Non-Invasive Aesthetic Care in Sunny Isles Beach
Manhattan Laser Spa Continues to Set the Standard for Non-Invasive Aesthetic Care in Sunny Isles Beach

Globe and Mail

time11 hours ago

  • Globe and Mail

Manhattan Laser Spa Continues to Set the Standard for Non-Invasive Aesthetic Care in Sunny Isles Beach

Manhattan Laser Spa expands in Sunny Isles Beach, offering expert laser hair removal, Botox, and dermal fillers under Mila Alishaev's leadership. Sunny Isles Beach, FL - July 24, 2025 - Manhattan Laser Spa, led by Founder and CEO Mila Alishaev, is proud to reaffirm its commitment to cutting-edge, non-invasive aesthetic solutions at its Sunny Isles Beach location. With a growing reputation for excellence, the spa continues to offer clients in South Florida personalized, high-quality treatments that prioritize safety, innovation, and natural-looking results. At the heart of this continued success is a focus on clinical expertise, modern technology, and a personalized approach to beauty. Alishaev, a seasoned entrepreneur and visionary in the cosmetic industry, emphasizes that every service offered at Manhattan Laser Spa is guided by a singular goal: helping clients look and feel their best without compromising on safety or comfort. Expanding Access to Leading Services in Cosmetic Enhancement With increasing demand for non-surgical beauty procedures, Manhattan Laser Spa has become a trusted name in South Florida. Its Sunny Isles Beach facility offers a full suite of advanced treatments, including laser hair removal, designed to provide long-lasting results with minimal discomfort. This location also specializes in FDA-approved injectables like Botox, a solution widely used to minimize the appearance of fine lines and wrinkles. For those seeking more volume or facial contouring, the spa provides expertly administered dermal fillers, customized to complement individual facial structure and aesthetic goals. These services are performed under the supervision of trained professionals using state-of-the-art equipment, ensuring that every treatment meets the highest standard of care. Alishaev notes, 'Our goal is to make the most trusted aesthetic services accessible to clients in South Florida, while maintaining a strong commitment to medical integrity and visible results.' A Vision Driven by Excellence and Innovation Mila Alishaev's leadership is central to the spa's continued success and expansion. Her passion for innovation and dedication to her clients' satisfaction has not only elevated the spa's reputation but has also helped set a new standard in the aesthetic care industry. By consistently investing in the latest technologies and staff training, she ensures Manhattan Laser Spa remains at the forefront of the cosmetic field. 'Cosmetic enhancements are no longer just about trends; they're about confidence, health, and the power of choice,' says Alishaev. 'At Manhattan Laser Spa, we don't believe in one-size-fits-all. Every client deserves a customized approach based on their individual goals and skin profile.' As the beauty industry evolves, Manhattan Laser Spa remains a leading example of what modern, client-focused care should look like. With its expanded offerings in Sunny Isles Beach and continued dedication to safety and innovation, the spa is positioned to remain a leader in aesthetic medicine for years to come. About Manhattan Laser Spa Founded by Mila Alishaev, Manhattan Laser Spa is a full-service medical spa specializing in non-invasive beauty solutions. With multiple locations, including its growing presence in Sunny Isles Beach, the spa has earned a strong reputation for quality care and natural results. Services include laser hair removal, Botox, dermal fillers, skin rejuvenation, and more. For more information or to schedule a consultation, visit Media Contact Company Name: Manhattan Laser Spa Contact Person: Mila Alishaev Email: Send Email Phone: 7867514733 Address: 16850, Collins Ave #105 City: Sunny Isles Beach State: Florida, 33160 Country: United States Website:

Pura Scents recalling more than 850,000 diffusers as magnet issue may cause ingestion hazard
Pura Scents recalling more than 850,000 diffusers as magnet issue may cause ingestion hazard

CTV News

time12 hours ago

  • CTV News

Pura Scents recalling more than 850,000 diffusers as magnet issue may cause ingestion hazard

Pura Scents is recalling more than 850,000 diffusers because some magnets may detach and cause a possible ingestion hazard to children. The company is recalling about 851,400 Pura 4 Smart Home Fragrance Diffusers with detachable covers. It said an additional 1,100 were sold in Canada. Pura Scents said that the magnets on the inside cover of the product can detach, posing an ingestion hazard to children. When high-powered magnets are swallowed, the ingested magnets can attract each other, or other metal objects, and become lodged in the digestive system. This can result in perforations, twisting or blockage of the intestines, infection, blood poisoning and death. The company has received three reports of magnets detaching from the cover. No injuries have been reported. The diffusers were sold at Target, Scheels and other stores nationwide from August 2023 through May 2025 for about US$50. They were also sold online through Pura's website, as well as online at Amazon, Target and Scheels. Pura Scents is offering a free replacement cover. Consumers are advised to immediately dispose of the existing detachable cover and to keep the diffusers out of the reach of children and pets. To receive the free replacement cover, individuals may contact Pura Scents at 855-394-5292 from 9 a.m. to 5 p.m. MT Monday through Friday. The company can also be emailed at replacement@ Consumers may also visit the company's website and click on 'Recall' at the bottom of the page for more information. Michelle Chapman, The Associated Press

How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?

Globe and Mail

time13 hours ago

  • Globe and Mail

How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company's primary focus is on diabetes and obesity drugs, the oncology franchise also remains a key contributor to the top line. Sales from the oncology segment accounted for over 15% of Lilly's first-quarter revenues, which grew more than 11% year over year. Our model estimates second-quarter 2025 sales for the overall oncology unit to be $2.4 billion, indicating more than 11% year-over-year growth. A significant portion of these revenues is likely to have been generated from sales of the company's blockbuster breast cancer drug, Verzenio. Sales of this drug are expected to have been driven by increased demand and higher realized prices during the quarter, partially offset by currency headwinds and competitive dynamics. Sales of RET inhibitor Retevmo and newer lymphoma drug Jaypirca are also likely to have contributed positively to top-line growth during the quarter. However, these gains might have been partially offset by the declining sales of older cancer drugs like Alimta and Cyramza, which are being impacted by competition from immuno-oncology agents in the United States. Though Lilly's oncology portfolio is contributing meaningfully, investor focus will largely remain on blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity). Investors will closely track their sequential growth and market share trends in the upcoming second-quarter results on Aug. 7. Competition in the Oncology Space Other bigger players in this area are AstraZeneca AZN, Merck MRK and Pfizer PFE. For AstraZeneca, oncology sales now account for nearly 41% of total revenues. Growth in AZN's oncology franchise is being driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for nearly half of Merck's product revenues. Pfizer's oncology segment — comprising drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev — currently accounts for more than 27% of its total revenues. LLY's Price Performance, Valuation and Estimates Shares of Lilly have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 29.66 times forward earnings, higher than its industry's average of 14.91. However, the stock is trading below its five-year mean of 34.54. EPS estimates for 2025 have risen from $21.92 to $21.99, while those for 2026 have declined from $30.91 to $30.79 over the past 30 days. Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store